The India sales of thyroid function test are estimated to be worth USD 55.3 million in 2025 and anticipated to reach a value of USD 97.2 million by 2035. Sales are projected to rise at a CAGR of 5.8% over the forecast period between 2025 and 2035. The revenue generated by thyroid function test in 2024 was USD 52.9 million.
India is witnessing the high adoption of point-of-care, testing devices, revolutionizing the thyroid function test market, which is a pivotal driver in the market. It consists of portable, user-friendly devices that provide rapid and accurate results for diagnostics, solving one major issue - time-to-detection and management of thyroid disorders.
The approach is especially helpful for underserved and remote areas. The fact that POC devices bypass the logistical challenges associated with centralized laboratories makes them convenient in areas where healthcare infrastructure in rural regions is often constrained by limited resources. Delivering results within minutes empowers healthcare providers to initiate immediate interventions, which significantly improves patient outcomes.
India Thyroid Function Test Industry Assessment
| Attributes | Key Insights |
|---|---|
| Estimated Size, 2025 | USD 55.3 million |
| Projected Size, 2035 | USD 97.2 million |
| Value-based CAGR (2025 to 2035) | 5.8% |
Manufacturers are enhancing the POC testing devices with new-age features such as wireless connectivity and synchronization of data with healthcare management systems. This has enabled easy data transfer, making remote monitoring and follow-up care possible, mainly for chronic thyroid conditions. These technologies improve diagnostic efficiency while aligning with the digital transformation of India's health sector.
From here, the application of POC devices is broadening to urban zones among individuals and working professionals as these are seeking faster, easy, and reliable self-care health screening services. Increased applications of POC testing integrated with telemedicine also aim to cope up with increased needs for effective, accessible thyroid diagnosis. Through such integration, all aspects of patient care will be covered where remote consultation through a healthcare provider is possible following actual diagnostic feedbacks.
Thus, the adoption of POC testing devices is revolutionizing the thyroid function test market in India, bridging healthcare gaps, and paving the way for enhanced diagnostic accuracy and accessibility.
Explore FMI!
Book a free demo
The below table presents the expected CAGR for the India thyroid function test market over several semi-annual periods spanning from 2025 to 2035. In the first half (H1) of the decade from 2024 to 2035, the business is predicted to surge at a CAGR of 6.8%, followed by a slightly lower growth rate of 6.4% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 6.8% (2024 to 2035) |
| H2 | 6.4% (2024 to 2035) |
| H1 | 5.8% (2025 to 2035) |
| H2 | 5.5% (2025 to 2035) |
Moving into the subsequent period, from H1 2025 to H2 2035, the CAGR is projected to decrease slightly to 5.8% in the first half and decrease moderately at 5.5% in the second half. In the first half (H1) the market witnessed an increase of 100.00 BPS while in the second half (H2), the market witnessed a decrease of 90.00 BPS.
The Increasing Prevalence of Thyroid Disorders Is a Significant Driver Propelling the Market Growth.
The increasing prevalence of thyroid disorders, including hypothyroidism, hyperthyroidism, and thyroid nodules, is a significant driver propelling the growth of the thyroid function test market in India. The growing burden of thyroid diseases combined with increased awareness and greater patient access to healthcare has resulted in higher demand for available distantly located diagnostics tests in this region.
Growing burden of thyroid diseases combined with the limited number of healthcare providers and equipment available would result in high demand for the available distantly-located diagnostic services in this region.
The main reasons for increased thyroid problems include iodine deficiency, which really remains a concern in areas where diets lack proper iodine intake. Autoimmune diseases like Hashimoto's thyroiditis along with Graves' disease also occur more often, which adds to the affected population. Modern lifestyle factors such as poor diet habits, high stress levels as well as inactive daily routines contribute to hormone imbalances that make people more likely to develop thyroid problems.
A larger patient base has, therefore been calling for faster and more reliable diagnostic results. Detection and tracking of thyroid illnesses early is central to proper control of the diseases. As such, the current use of many tests that determine T3, T4, and TSH levels are inevitable as they help one establish the state of abnormality and consequently the treatments needed. Their importance is greater among the more susceptible populations.
This increasing burden of thyroid disorders makes efficient diagnostic solutions more pressing, thereby acting as an important driving factor for the thyroid function test market in India.
Advancements in Immunoassay Techniques Driving the India Thyroid Function Test Market
Latest advancements in testing relating to thyroid are taking place in India thanks to the novel methods such as chemiluminescent immunoassays and enzyme-linked immunosorbent assays. These are highly efficient in detecting thyroid hormones such as T3, T4, and thyroid-stimulating hormone (TSH) with great precision. Knowing the state of severe symptoms would be of great importance in detecting thyroid-related issues, which may seriously affect health without any specific symptoms.
Chemiluminescent immunoassay (CLIA) is considered a favorite since it conducts numerous samples accurately and rapidly while providing very reliable results. ELISA is inexpensive and gives expected results hence can be used in city clinics and even rural health centers.
With more sophisticated testing techniques to detect thyroid disorders at an earlier stage, doctors start treatment immediately to prevent the occurence of fatal consequences from untreated thyroid conditions and complications. The use of modern automated testing equipment has accelerated the speed of the procedures thereby improving patient care.
More and more hospitals and laboratories in India are implementing such advanced techniques into their facilities as routine. The thyroid testing market is enlarging by all this referred modernization due to the huge demands for tests which are accurate but at the same time fast and available to all, no matter where they live.
Government and Private Sector Initiatives Driving the India Thyroid Function Test Market
The Indian government as well as private sector have always played a pioneering role in advancing the diagnostic structure, which has provided a boost in the growth process of the market for thyroid function testing. Healthcare support policies, subsidies as well as strategically planned collaborations facilitate access to and enhance diagnostic health services in difficult and remote inaccessible areas.
Initiatives such as the National Health Mission (NHM) are implemented by the government to expand diagnostic facilities in rural areas, meeting the healthcare needs of populations susceptible to thyroid disorders. Subsidized testing programs and awareness campaigns have increased public knowledge about thyroid health, which encourages early diagnosis and treatment.
PPPs supplement these efforts, as they involve private players bringing their resources and expertise to expand the reach and quality of diagnostic services.
Private healthcare companies and diagnostic businesses are crucial in driving innovation and improving facilities. They are investing in advanced tools, such as automated machines for immune response tests and devices that allow for on-site health testing. These improvements make thyroid function tests quicker and more accurate. Moreover, these companies are growing their operations in tier-2 and tier-3 cities, which helps reduce the healthcare gap between urban and rural areas.
Economic Constraints of the Target Population Impacting the India Thyroid Function Test Market
Financial challenges are a major obstacle to the growth of the thyroid function test market in India. Many people in low-income and rural areas cannot afford regular thyroid testing. Due to limited financial resources, they often focus on immediate health needs rather than on preventive or diagnostic tests, which can result in late or missed diagnoses of thyroid disorders.
Government efforts to make healthcare more affordable frequently fall short of addressing financial disparities across different demographics. High out-of-pocket healthcare expenses in India further discourage routine thyroid testing, particularly in areas without adequate health insurance coverage.
The costs associated with advanced diagnostic technologies, like chemiluminescent immunoassays (CLIA) and automated analyzers, make thyroid tests less accessible to poorer populations. Although more affordable point-of-care (POC) devices and mobile health units are available, their adoption is limited due to infrastructure problems and uneven distribution across regions.
These financial barriers emphasize the necessity for targeted strategies to improve access and foster market growth. Potential solutions include expanding insurance coverage, enhancing public-private partnerships, and promoting low-cost diagnostic alternatives to ensure broader access to thyroid function tests.
The India thyroid function test industry recorded a CAGR of 4.3% during the historical period between 2020 and 2024. The growth of thyroid function test industry was positive as it reached a value of USD 52.9 million in 2024 from USD 50.6 million in 2020.
The India thyroid function test market has grown extensively over the years due to a rapidly increasing number of patients affected with thyroid diseases, increased awareness about the diagnosis and treatment, and advancements in the diagnostic techniques.
Traditionally, thyroid function tests were performed mostly in bigger cities, and access in the rural sector was limited mainly because of lack of infrastructure and cost. However, the market has been revolutionized by the adoption of advanced diagnostic tools, including immunoassay technologies and point-of-care testing devices, which have improved accessibility, speed, and accuracy of testing even in remote areas.
The market is growing steadily, due to the efforts of the government and the private sectors, in the form of improvement in health infrastructure, free testing services, and raising awareness about thyroid health. Integration of cost-effective diagnostic solutions and telemedicine has further contributed toward the expansion of market growth.
Going forward, the market is set to increase because of continued advancements in diagnostic technologies, expanded adoption of AI and automation in laboratories, and increased accessibility of healthcare services in rural regions.
Personalized medicine with a better approach to treating thyroid disorders is also going to play a role in the development and usage of tests. In addition, the increasing adoption of POC testing and integration with digital health platforms will redefine patient care models and fuel market growth in the coming years.
Tier 1 companies comprise market leaders with a significant market share of 49.3% in India market. These companies engage in strategic partnerships and acquisitions to expand their product portfolios and access cutting-edge technologies.
Additionally, they emphasize extensive clinical trials to validate the efficacy and safety of their products. Prominent companies in tier 1 include Thyrocare Technologies Ltd., Dr. Lal PathLabs, Metropolis Healthcare Ltd. and SRL Diagnostics
Tier 2 companies include mid-size players having presence in specific regions and highly influencing the local market and holds around 21.7% market share. They typically pursue partnerships with multispecialty hospitals and research organizations to leverage emerging technologies and expedite product development.
These companies often emphasize agility and adaptability, allowing them to quickly bring new products to market, additionally targeting specific types medical needs. Additionally, they focus on cost-effective production methods to offer competitive pricing. Prominent companies in tier 2 include Apollo Diagnostics, Quest Diagnostics India, Suburban Diagnostics and Abbott India.
Finally, Tier 3 companies, such as FiRoche Diagnostics India and Siemens Healthineers India and others. They specialize in specific products and cater to niche markets, adding diversity to the industry.
Overall, while Tier 1 companies are the primary drivers of the market, Tier 2 and 3 companies also make significant contributions, ensuring the thyroid function test sales remains dynamic and competitive.
The section contains information about the leading segments in the industry. By test type, the TSH (thyroid-stimulating hormone) test segment holds the highest share of 60.1% in 2025.
| By Test Type | Value Share (2025) |
|---|---|
| TSH (Thyroid Stimulating Hormone) | 60.2% |
The assessment of TSH is significant in diagnosing conditions that involve disorders in the thyroid gland, for instance, hypothyroidism and hyperthyroidism. It is most used as a marker for evaluating the function of the thyroid due to its extreme sensitivity in the identification of even mild or subclinical imbalances.
The fact that it is relatively cheaper and easy to administer further makes the TSH test widely used in both urban and rural locations. It can also be very easily included within routine health checks, which explains its popularity amongst those seeking preventive healthcare. This is because its ability to indicate the functionality of the thyroid gland makes it a gold standard test for diagnosing thyroid conditions. With more people opting for routine thyroid function testing, TSH is increasingly being ordered in preference to the other thyroid markers such as T3 and T4 in India.
| By End User | Value Share (2025) |
|---|---|
| Hospitals | 53.0% |
Hospitals are the most dominant market players in the India thyroid function test market, primarily due to their complete healthcare services, advanced diagnostic capabilities, and high patient volumes. As primary healthcare providers, hospitals offer specialized thyroid diagnostic testing, including TSH, T3, and T4 assays, catering to patients with a broad spectrum of thyroid disorders.
Advanced technologies, including immunoassay analyzers, are available in well-established laboratory facilities in hospitals, which can give immediate and accurate results. Hospitals also avail of the presence of endocrinologists and specialized medical teams, ensuring proper diagnosis and treatment.
With the increased trend in preventive health check-ups including tests for thyroid function, more tests are being performed in hospitals. Hospitals continue to be the first preference for thyroid diagnosis with improved healthcare access and reduced cost of healthcare. The availability of integrated healthcare services and the strong patient base will ensure that the hospitals continue dominating the market for thyroid function testing.
The companies are using strategies to stay competitive, such as product differentiation through innovative formulations, strategic partnerships with healthcare providers for distribution. Another key strategic focus of these companies is to actively look for strategic partners to bolster their product portfolios and expand their India presence.
Recent Industry Developments in thyroid function test Market
The India thyroid function test market is projected to witness CAGR of 5.8% between 2025 and 2035.
The India thyroid function test industry stood at USD 52.9 million in 2024.
The India thyroid function test market is anticipated to reach USD 97.2 million by 2035 end.
The key players operating in the India thyroid function test market include Thyrocare Technologies Ltd., Dr. Lal PathLabs, Metropolis Healthcare Ltd., SRL Diagnostics, Apollo Diagnostics, Quest Diagnostics India, Suburban Diagnostics, Abbott India, Roche Diagnostics India and Siemens Healthineers India.
Generalized Myasthenia Gravis Management Market - Growth & Treatment Advances 2025 to 2035
Hutchinson-Gilford Progeria Syndrome Market Growth – Innovations & Therapies 2025 to 2035
Home Infusion Therapy Devices Market - Growth & Forecast 2025 to 2035
Human Combinatorial Antibody Libraries (HuCAL) Market - Trends & Forecast 2025 to 2035
Home Healthcare Market Growth - Trends, Innovations & Forecast 2025 to 2035
Dental 3D Printing Material Market Trends, Growth & Forecast by Material, Product, and Region through 2035
India Thyroid Function Test Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
